Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA
- PMID: 17018633
- DOI: 10.1158/0008-5472.CAN-06-1617
Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA
Abstract
Despite successes in animal models, cancer gene therapy with small interfering RNAs (siRNA) is hindered by the lack of an optimal delivery platform. We examined the applicability of the replication-competent, oncolytic adenovirus, ONYX-411, to deliver a mutant K-ras siRNA transgene to human cancer cells. Proof-of-principle studies showed an additive tumor growth-inhibitory response through siRNA-mediated K-ras knockdown and ONYX-411-mediated cancer cell lysis. A novel construct, termed Internavec (for interfering RNA vector), was generated by cloning a K-ras(v12)-specific siRNA(ras-4) hairpin construct under the control of the human H1 promoter into the deleted E3b region of ONYX-411. Internavec acquired an increase in potency of approximately 10-fold in human cancer cells expressing the relevant K-ras(v12) mutation (H79, H441, and SW480), as defined by a reduction in the effective dose needed to achieve 50% growth inhibition (ED(50)). Internavec remained attenuated in nonmalignant epithelial cells. Daily intratumoral injections of Internavec (five daily injections of 1 x 10(8) plaque-forming units) significantly reduced the growth of s.c. H79 pancreatic cancer xenografts in nu/nu mice by 85.5%, including complete growth suppression in three of five mice. Parental ONYX-411 or ONYX-411-siRNA(GFP) was markedly less effective (47.8% growth reduction, P = 0.03; and 44.1% growth reduction, P = 0.03, respectively). siRNA(ras) transgene activity contributed to cell cycle blockage, increased apoptosis, and marked down-regulation of Ras signaling-related gene expression (AKT2, GSK3 beta, E2F2, and MAP4K5). These findings indicate that Internavec can generate a two-pronged attack on tumor cells through oncogene knockdown and viral oncolysis, resulting in a significantly enhanced antitumor outcome.
Similar articles
-
Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.Gene Ther. 2000 Dec;7(23):2041-50. doi: 10.1038/sj.gt.3301331. Gene Ther. 2000. PMID: 11175317
-
[Study of growth inhibition of lung cancer cells by siRNA targeting mutant K-ras gene in vitro and in vivo].Zhonghua Wai Ke Za Zhi. 2007 Sep 15;45(18):1267-70. Zhonghua Wai Ke Za Zhi. 2007. PMID: 18067742 Chinese.
-
Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition.Gene Ther. 2008 May;15(9):635-51. doi: 10.1038/gt.2008.3. Epub 2008 Feb 14. Gene Ther. 2008. PMID: 18273054
-
Small interfering RNA for experimental cancer therapy.Curr Opin Mol Ther. 2005 Apr;7(2):114-24. Curr Opin Mol Ther. 2005. PMID: 15844618 Review.
-
Targeting gene-virotherapy of cancer.Cell Res. 2006 Jan;16(1):25-30. doi: 10.1038/sj.cr.7310005. Cell Res. 2006. Retraction in: Cell Res. 2006 Aug;16(8):740. doi: 10.1038/sj.cr.7310088. PMID: 16467873 Retracted. Review.
Cited by
-
A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA.Theranostics. 2015 Apr 20;5(8):818-33. doi: 10.7150/thno.11335. eCollection 2015. Theranostics. 2015. PMID: 26000055 Free PMC article.
-
siRNA targeting Livin decreases tumor in a xenograft model for colon cancer.World J Gastroenterol. 2011 May 28;17(20):2563-71. doi: 10.3748/wjg.v17.i20.2563. World J Gastroenterol. 2011. PMID: 21633662 Free PMC article.
-
Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity.Mol Ther. 2010 Nov;18(11):1972-82. doi: 10.1038/mt.2010.163. Epub 2010 Aug 10. Mol Ther. 2010. PMID: 20700112 Free PMC article.
-
Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus.J Ovarian Res. 2022 Dec 7;15(1):130. doi: 10.1186/s13048-022-01054-5. J Ovarian Res. 2022. PMID: 36476493 Free PMC article.
-
Unleashing the Full Potential of Oncolytic Adenoviruses against Cancer by Applying RNA Interference: The Force Awakens.Cells. 2018 Nov 23;7(12):228. doi: 10.3390/cells7120228. Cells. 2018. PMID: 30477117 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous